Topadur is a biopharmaceutical company that designs new drugs targeting the cGMP-Enzyme Regulation System. Topadur's compounds regulate the activity of sGC and PDE5 enzymes to increase the level of cGMP, which aims to enable blood circulation and correct insufficient cell-cell communication.

Topadur

Topadur Pharma AG is a Swiss biopharmaceutical start-up based in Schlieren, Zurich. The company was founded in 2015 by experienced scientists that combine several years of expertise in R&D Pharma. Topadur’s vision is to improve patients’ quality of life by providing highly effective and safe drugs for unmet medical conditions. 
Topadur has discovered and developed new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related diseases like chronic wounds, skin fibrosis, age-related macular degeneration, colorectal cancer, hair loss and skin aging.

Topadur Pharma AG

Today, on #WorldSclerodermaDay 2024, Topadur Pharma AG stands with the 2.5 million people worldwide affected by this rare autoimmune disorder. 
Systemic sclerosis (SSc) and its complications, like digital ulcers and Raynaud’s phenomenon, can severely impact patients' daily lives. 

At Topadur, we're committed to making a difference:

🔬 Our lead candidate, TOP-N53, is advancing to a Phase 2a clinical trial for digital ulcers in SSc patients. This trial is part of an Innosuisse-funded Start-up Innovation Project.
🤝 We're collaborating with field experts to bring hope to those affected by SSc.

Follow us for updates on this exciting journey as we work towards innovative solutions for SSc patients.

#Scleroderma #RareDiseaseResearch #ClinicalTrials #BiotechInnovation #TOPN53 #Topadur

Team Topadur had an exciting time in South Korea!!! 😀 

Jaan Strang and Tobias Braun from Topadur Pharma AG visited our collaborators at Yonsei University and Juvic Inc. in the context of our transnational Innosuisse project. They had dynamic interactions with the South Korean partners. The core focus of the visit was coordinating project activities and discussions regarding project plans, knowledge transfer, and harmonization for improved disease management in Raynaud’s phenomenon in Systemic sclerosis. During the visit, our partners shared the latest developments in their microneedle technology to the extent that we could test their first marketed product, Needeep. 

This visit strengthened our collaboration even further! We look forward to new developments in this project. 

#Topadur #Yonsei #Juvic #startup #TOPN53

Topadur Pharma AG is delighted to announce that we have signed a partnering and licensing agreement with Oshen Bio. This binding agreement is to develop the liquid topical formulation of TOP-M119 for treating Alopecia. We are excited for the upcoming developments in this journey. 
"Based on our pre-clinical data, we are convinced that TOP-M119 can become a game changer in treating hair loss and improving hair quality. The partnering agreement with Oshen helps to speed up the development and provide faster access to patients,” said Pascal Brenneisen, CEO of Topadur Pharma AG. 

#Topadur #Oshenbio #Alopecia #TOPM119 #innovation #startup #scaleup

Today, on World Health Day, the World Health Organization highlights that health is a fundamental human right with the theme "My health, my right".
Topadur Pharma AG is proud to highlight its continuous efforts for health betterment and accessibility with our novel drug candidates for diseases with unmet medical needs.

With our innovative approach, we aspire to exploit the potential of the NO/cGMP signaling pathway to repair gene expression and regulate microcirculation in several diseases. Topadur focuses on disruptive therapies for Wound Healing, Skin Fibrosis, Ophthalmology, Medical Cosmetics (Alopecia, Skin Aging), Oncology & Lung Fibrosis.
 
Our commitment to health innovation is driven by a mission: to improve patient life globally. Discover more about our research and development and the potential of NO/cGMP modulation at our website www.topadur.com.

#WorldHealthDay #MyHealthMyRight #Innovation #Topadur

Today, on World Diabetes Day, TOPADUR PHARMA AG thinks about the 537 million people worldwide living with Diabetes. Globally 1 in 10 adults suffer from Diabetes, and more than 90% of these have type 2 Diabetes. There are severe complications associated with Diabetes and these patients suffer on a daily basis. 

We are engaging in various research programs with our candidates TOP-N53 and TOP-V122 against Diabetic Foot Ulcers and Diabetic Retinopathy respectively. These severe complications of Diabetes are often accompanied by impaired blood circulation. We believe that our innovative drug candidates will help these patients by improving the blood circulation in the affected areas and alleviate their pain. 

We are excited about the results we will get together with our research partners in the future.

#WorldDiabetesDay #Topadur #Diabeticfootulcers #Diabeticretinopathy #Startup #Innovation #scaleup 🚀

Reto Naef, Pascal Brenneisen, Christian Ludin, Rita de Brito Francisco, Jaan Strang, Yoshita Bhide, Esra Lone-Kapaklikaya, Tobias Braun, Michael Spoerri

👏 Exciting results
 "Radiotherapy combined with TOP-V122 is a novel therapeutic strategy for colorectal carcinoma."

💫 With great enthusiasm, Topadur Pharma AG would like to share with you the exciting research work carried out as part of a recently completed Innosuisse innovation Project. Within the project, the therapeutic potential of our drug candidate TOP-V122 in combination with radiotherapy against colorectal cancer was investigated.

🔬 These Findings were presented with a poster entitled “Radiotherapy combined with TOP-V122 is a novel therapeutic strategy for colorectal carcinoma” by Alba Sánchez Fernández, PhD  at 16th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology in Oslo, Norway 2023.

Dr. Sanchez-Fernandez is part of the Laboratory for Applied Radiobiology headed by Prof. Dr. Martin N. Pruschy within the Department of Radiation Oncology at University of Zurich. These project achievements reflect the dedication and hard work of our research partners. The whole Topadur team is extremely grateful for this and looks forward to more excellent work together with them. 

#Topadur #UZH #Innosuisse #TOPV122 #Colorectalcancer #Cancerresearch #Innovation #Startup

COM:TOPADUR

Topadur

Financials Not Available